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Abstract
Background: Claudins are membrane proteins that play critical roles in tight junction (TJ) formation and function. Members
of the claudin gene family have been demonstrated to be aberrantly regulated, and to participate in the pathogenesis of
various human cancers. In the present study, we report that claudin-11 (CLDN11) is silenced in gastric cancer via
hypermethylation of its promoter region.
Methodology/Principal Findings: Levels of CLDN11 methylation and mRNA expression were measured in primary gastric
cancer tissues, noncancerous gastric mucosae, and cell lines of gastric origin using quantitative methylation-specific PCR
(qMSP) and quantitative reverse transcriptase-PCR (qRT-PCR), respectively. Analyses of paired gastric cancers and adjacent
normal gastric tissues revealed hypermethylation of the CLDN11 promoter region in gastric cancers, and this
hypermethylation was significantly correlated with downregulation of CLDN11 expression vs. normal tissues. The CLDN11
promoter region was also hypermethylated in all gastric cancer cell lines tested relative to immortalized normal gastric
epithelial cells. Moreover, CLDN11 mRNA expression was inversely correlated with its methylation level. Treatment of
CLDN11-nonexpressing gastric cancer cells with 5-aza-29-deoxycytidine restored CLDN11 expression. Moreover, siRNA-
mediated knockdown of CLDN11 expression in normal gastric epithelial cells increased their motility and invasiveness.
Conclusions/Significance: These data suggest that hypermethylation of CLDN11, leading to downregulated expression,
contributes to gastric carcinogenesis by increasing cellular motility and invasiveness. A further understanding of the
mechanisms underlying the role of claudin proteins in gastric carcinogenesis will likely help in the identification of novel
approaches for diagnosis and therapy of gastric cancer.
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Introduction
Gastric cancer (GC) remains the second most-common cause of
cancer deaths globally. It is one of the most lethal malignancies
and a leading cause of cancer deaths in developing countries, with
overall 5-year survival rates below 20% [1,2].
Studies of GCs and their preneoplastic precursor lesions have
identified several genetic and epigenetic alterations, including
microsatellite instability, point mutations, and loss of heterozygos-
ity (LOH) affecting tumor suppressor genes (TSGs) [3–6].
Nevertheless, the molecular pathogenesis of GC is still incom-
pletely understood.
Epigenetic alterations are extremely important in cancer
development and progression [7]. Transcriptional inactivation of
tumor suppressor genes via aberrant promoter hypermethylation
of CpG islands, causing permanent gene silencing, is a major
epigenetic mechanism of TSG inactivation.
Previously, studies have been published on promoter hyper-
methylation in GCs and their premalignant precursors [8–10].
p16INK4A and p15INK4B were among the first genes to show
hypermethylation in GCs [11]. Our group and others subsequent-
ly discovered hypermethylation of the hMLH1 DNA mismatch
repair gene in GCs exhibiting frequent microsatellite instability
(MSI-H) [12–14]. We also showed that hypermethylation of the E-
cadherin (CDH1) gene occurs frequently in GCs [15].
A pilot microarray-based genome-wide search conducted by our
group, performed to discover novel epigenetically silenced genes in
gastric carcinogenesis, identified claudin-11 (CLDN11), a tight
junction (TJ) protein, as a potential target of epigenetic
inactivation in gastric cancers (unpublished data).
Claudin-11 belongs to the family of claudin proteins, which
contains more than 23 members. Members of the claudin family are
expressed in a highly tissue-specific manner in a variety of normal
and neoplastic tissues [16]. Claudins are transmembrane proteins
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intercellular junctionscritical inthe paracellulartransportof solutes,
as well as in maintaining cell polarity. Tumor cells commonly
exhibit structural and functional deficiencies in their TJs [17].
In recent years, a number of studies have demonstrated aberrant
expression of claudin proteins in various cancer types [18], [16].
Several of these studies found dysregulation of claudin protein
expression via promoter hypermethylation. Hypermethylation-
induced silencing of claudin-7 expression was previously reported
in breast [19] and colorectal [20] carcinomas. Claudin-6 is also
epigenetically silenced in breast cancer [21], while claudins -3 and -
4 are epigenetically regulated in ovarian cancer cells [22,23].
The current study identifies and reports, to our knowledge for
the first time, that the CLDN11 promoter region is hypermethylated
in GC tissues and cell lines. Moreover, while CLDN11 mRNA was
expressed in all primary noncancerous gastric mucosal tissues, as
well as in an immortalized normal gastric epithelial cell line, it was
silenced in all GC tissues and cell lines examined. Interestingly,
siRNA-mediated downregulation of CLDN11 in CLDN11-express-
ing gastric cells was also associated with cancer-related phenotypic
changes, specifically increased cell motility and invasiveness.
Materials and Methods
Cell Lines and Clinical Tissue Specimens
Immortalized human normal gastric epithelial cells (HFE145)
were obtained from Dr. Duane T. Smoot (Howard University) and
GC cell lines AGS, SIIA, MKN28, KATOIII, and SNU-1 were
obtained from ATCC. All cell lines were cultured and maintained
in RPMI 1640 medium supplemented with 10% fetal bovine
serum and 1% antibiotic-antimycotic solution (Invitrogen).
Paired primary gastric normal and tumor tissues were collected
at the Johns Hopkins Hospital (JHH). Specimens were snap-frozen
immediately after resection.
Ethics Statement
Johns Hopkins University (JHU) Institutional Review Board
(IRB) approval was obtained for all the cases included in the study.
Caseswereobtained fromJHUsurgical pathologyunderJHUIRB-
approved exemption 02-07-19-05e under rule 45 CFR 46.101(b),
which waives the requirements for obtaining patient consent.
Purification and Preparation of Genomic DNA and Total RNA
Genomic DNA was extracted from snap-frozen tissue samples
or cell lines using a DNeasy Blood & Tissue Kit (QIAGEN,
Valencia, CA) according to the manufacturer’s protocol. Total
RNA was extracted with Trizol reagent (Invitrogen). Extracted
DNA and RNA were quantified using a NanoDrop ND-1000
Spectrophotometer (NanoDrop, Wilmington, DE).
Quantitative Methylation-Specific PCR (qMSP)forClaudin-11
Genomic DNAs obtained from 36 patient samples comprising
18 GC and 18 matched noncancerous stomach mucosal (NS)
tissues, as well as from various gastric cell lines, were subjected to
qMSP. qMSP was performed as described previously, with minor
modifications [24]. In brief, bisulfite treatment of genomic DNAs
was performed using an EpiTect Bisulfite Treatment Kit
(QIAGEN, Valencia, CA). An MSP amplicon and TaqMan
probe to detect completely methylated DNA were designed to
include multiple CpG sites in the 59-UTR region of CLDN11 gene.
CLDN11-specific primers and probe sequences used were: forward
primer 59 CGCGATTGGTCGGCGCGTTTC 39; reverse prim-
er 59 GACGAAAACAACAACGCTACT 39; TaqMan probe
59TCGGAGTCGCGGGGTTTAAAGAG 39. CpGenome Uni-
versal Methylated DNA (Chemicon International, Temecula, CA)
served as a positive control, and serial dilutions of it were used to
plot a standard curve. qMSP with TaqMan probe were performed
on an iQ5 thermal cycler (BioRad, Hercules, CA) using iQ
Supermix (ibid.). Fifty cycles of PCR amplification starting with
50 ng of bisulfite-treated genomic DNA were performed in
triplicate, according to the manufacturer’s protocol. Duplex
PCR with b-actin (ACTB) primer and probe sequences containing
no CpGs were performed for normalization. The primer and
probe sequences used were as published previously [24].
Normalized methylation value (NMV) was defined as follows:
NMV=(CLDN11-S/CLDN11-FM)/(ACTB-S/ACTB-FM) * 100,
where CLDN11-S and CLDN11-FM represent CLDN11 methyla-
tion levels in the sample and fully methylated DNAs, respectively,
while ACTB-S and ACTB-FM correspond to b-actin in the sample
and fully methylated DNAs, respectively. Whole-genome ampli-
fied DNA (WGA) was used as an unmethylated negative control.
Quantitative Reverse Transcription-PCR Analysis
The CLDN11 RT-PCR amplicon was designed to overlap an
intron-exon boundary in order to exclude genomic DNA (gDNA)
amplification. Primer sequences were as published previously [18].
One-step qRT-PCR was performed as described previously [24],
using a Quantitect SYBRA RT-PCR kit (QIAGEN, Valencia, CA),
according to the manufacturer’s protocol. CLDN11expression was
normalized to b -actin expression. Total RNA from HFE145 cells
was used for the standard curve. (CLDN11-S/CLDN11-C)/(ACTB-S/
ACTB-C), where CLDN11-S and CLDN11-C represent CLDN11
mRNA expression levels in the test sample and control mRNAs,
respectively, while ACTB-S and ACTB-C correspond to b-actin
expression levelsinthe testsampleandcontrol mRNAs,respectively.
5-Aza-29-Deoxycytidine (5-Aza-dC) Treatment
AGS is a GC cell line manifesting hypermethylation of the
CLDN11 promoter in conjunction with absent CLDN11 mRNA
expression. 5-aza-29-deoxycitidine (5-aza-dC) treatment of cells
was performed as described previously [24]. In brief, the GC cell
line AGS (ATCC catalog number CRL-1739) was seeded at a
density of 2610
5 cells/ml in a T-75 flask. Twenty-four hours later,
cells were treated with 1 mM 5-aza-dC for 72 hours. Media
containing 5-aza-dC was replaced with freshly prepared media
every 24 hours. Cells were then harvested for total RNA
extraction. Total RNAs from AGS cells before and after 5-aza-
dC treatment were subjected to quantitative real-time RT-PCR
analysis.
Small Interfering RNA Knockdown Experiments
CLDN11-specific siRNA oligos were purchased from Ambion,
Inc. (Austin, TX). The HFE145 cell line, which is CLDN11
positive, was selected to study the effect of claudin-11 knockdown
on migration and invasion properties of gastric cells. Experiments
were conducted as described previously (Agarwal et al., 2005). Cells
cultured in 6-well plates were transfected with siRNA duplexes
using LipofectAMINE 2000 (Invitrogen), following the manufac-
turer’s instructions. Mock-transfections and nonspecific siRNA
duplexes were used as negative controls. Cells were treated for 48
to 72 hours to allow maximum knockdown, after which they were
either harvested for Western blot analysis or used for migration
and invasion assays.
Western Blot Analysis of Claudin-11 in Gastric Cell Lines
Confluent cell cultures were washed with HBSS (Invitrogen)
and whole cell lysates were made using lysis buffer: 62.5 mmol/L
Claudin-11 and Gastric Cancer
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concentration was determined using a bicinchoninic acid (BCA)
assay kit (Pierce, Rockford, IL). Twenty micrograms of total
proteins were separated by 10% to 20% SDS-PAGE on Tris-
Glycine gels (Invitrogen) and transferred to polyvinylidene
difluoride membranes (Millipore Corp., Bedford, MA). The
membranes were blocked with 5% nonfat dry milk, washed in
TBST buffer, and probed with an anti-claudin-11 antibody
(Zymed, San Francisco, CA). Blots were then washed and
incubated in horseradish peroxidase-conjugated secondary anti-
body (anti-rabbit IgG: 1:10,000; Amersham Pharmacia Biotech,
Piscataway, NJ). For detection, chemiluminescence was carried
out using an enhanced chemiluminescence kit (Amersham
Pharmacia Biotech).
Cell Invasion and Migration Assay
Invasiveness of siRNA-transfected cells was determined using
Matrigel-coated invasion chamber inserts (24-well-format with 8-
mm pores, BD Biosciences) using a modified Boyden chamber
assay [25]. Cells were cultured to approximately 80% confluency
Figure 1. Promoter methylation and mRNA expression levels of claudin-11 (CLDN11) in clinical specimens. This figure illustrates the
promoter methylation and mRNA expression levels of CLDN11 in paired gastric cancer (GC) and noncancerous gastric mucosal (NS) tissues. A)
Quantitative methylation-specific PCR (qMSP) for CLDN11 in primary tissues. Genomic DNA extracted from 18 GC and 18 matched NS tissues were
subjected to qMSP analysis using MSP amplicon and TaqMan probe designed to include multiple CpG sites in the 59-UTR region of CLDN11 gene.
CpGenome UniversalMethylated DNA (Chemicon International, Temecula, CA) was used as a fully methylated positive control. Duplex PCR with b-actin
(ACTB) primer and probe sequences containing no CpGs were performed for normalization. Normalized methylation value (NMV) was defined as
follows: NMV=(CLDN11-S/CLDN11-FM)/(ACTB-S/ACTB-FM) * 100, where CLDN11-S and CLDN11-FM represent CLDN11 methylation levels in the sample
and fully methylated DNAs, respectively, while ACTB-S and ACTB-FM correspond to b-actin in the sample and fully methylated DNAs, respectively. This
one-dimensional scatterplot demonstrates significantly high CLDN11 promoter methylation levels in the GC specimens when compared to the NS
specimens (P,0.001). Whole-genome amplified DNA (WGA) used as an unmethylated negativecontrol did not show any amplification. The P value was
calculated using the paired Student’s t-test. B) CLDN11 mRNA expression in gastric tissues. Total RNA extracted from 18 paired NS and GC specimens
were subjected to CLDN11 specific RT-PCR. CLDN11 mRNA expression was normalized to b -actin mRNA expression in each sample. The P value was
calculated using the pairedStudent’s t-test.This plotdemonstrates that the CLDN11 mRNA expression levels were significantly lower to non-detectable
in the GC specimens, while most of the corresponding NS specimens had detectable CLDN11 mRNA levels (P,0.001). C) 2D-scatter plot of promoter
methylation and mRNA expression values in GC tissues. CLDN11 mRNA expression silencing is associated with promoter hypermethylation in GC
patients. This two-dimensional scatterplot demonstrates NEV values (Y-axis) and NMV values (X-axis) in the 18 paired NS and GC specimens.
doi:10.1371/journal.pone.0008002.g001
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trypsinized and viable cell counts taken. Approximately 50,000
cells were plated onto the top of each of each filter in serum-free
medium. An equal volume of the same medium containing 20%
FCS was placed in the lower chamber (i.e., the well beneath the
filter) to act as a chemoattractant. Assay plates were incubated at
37uC for up to 48 hrs. Cells that did not migrate or invade
through the pores of the Transwell inserts were manually
removed with a cotton swab. Cells present at the bottom of the
membrane were fixed in cold methanol for 10 min and then
stained with 0.01% crystal violet in 20% ethanol. After 10 min
incubation, the filters were washed thoroughly in water and
suspended in 200 mL of 5% acetic acid and 5% methanol.
Colorimetric readings were taken at OD595.E x p e r i m e n t sw e r e
repeated at least three times, with triplicates in each experiment.
To assess cell migration, assays were carried out essentially as
above, except that cells were plated on top of uncoated (Matrigel-
free) inserts.
Statistical Analysis
Statistical analyses were performed using Student’s t-test (SPSS,
version 16), with p,0.05 considered statistically significant.
Results and Discussion
We first tested our hypothesis that the CLDN11 promoter is
hypermethylated and that this hypermethylation correlates inverse-
ly with CLDN11 mRNA expression in primary GC tissues. Paired
primarygastricnormalandtumortissueswere collectedattheJohns
Hopkins Hospital (JHH). Specimens were obtained immediately
after resection and snap-frozen until use. Only cases obtained with
informed consent as approved by the Institutional Review Board
(IRB) were included in this project. Genomic DNAs were obtained
from 36 clinical specimens, comprising 18 GC and 18 matched
noncancerous gastric mucosal (NS) tissues. CLDN11 promoter
methylation levels in these samples were analyzed usingquantitative
real-timemethylation-specificPCR(qMSP).Figure1Adisplaysthe
Figure 2. Analysis of promoter methylation, mRNA and protein expression of claudin-11 in gastric cell lines. This figure illustrates the
claudin-11 promoter methylation, mRNA expression levels and protein expression in gastric cells lines. A) Quantitative methylation-specific PCR
(qMSP) for CLDN11. Genomic DNAs isolated from immortalized human normal gastric epithelial cells (HFE145) and GC cell lines AGS, SIIA, MKN28,
KATOIII, and SNU-1 obtained from ATCC were analyzed by qMSP. This Figure illustrates that the promoter region of CLDN11 gene is hypermethylated
in all GC cell lines relative to HFE145 cells. B) CLDN11 mRNA expression in gastric cell lines. Total RNAs from different gastric cell lines were subjected
to quantitative real-time RT-PCR analysis. As can be seen in this figure, HFE145 cells expressed very high levels of CLDN11 mRNA, while all five cancer
cell lines tested had very low or undetectable CLDN11 mRNA expression. C) Western blot analysis of claudin-11 expression in gastric cell lines. Total
cell lysates obtained from various gastric cell lines were probed with the anti-claudin-11 antibody. This figure illustrates that while the immortalized
normal gastric epithelial cell line, HFE145, expressed abundant claudin-11 protein, it could not be detected in various GC cell lines. Anti-b-actin
antibody was used as a loading control.
doi:10.1371/journal.pone.0008002.g002
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value of the CLDN11 promoter region in each specimen to a fully
methylated control DNA. CLDN11 NMVs were significantly higher
in GC specimens than in their matching NS tissues (P,0.001). To
assess whether CLDN11 promoter hypermethylation in GCs was
associated with silencing of CLDN11 expression, CLDN11 mRNA
levels were measured using quantitative real-time (qRT–PCR) in
RNAs extracted from the 36 specimens used for methylation
analysis. As demonstrated in Figure 1B, normalized expression
values (NEVs) of CLDN11 in GC specimens were significantly lower
than in paired NS samples (P,0.001). This data establishes that
CLDN11 promoter hypermethylation correlates with diminished or
silenced CLDN11 mRNA expression in primary GCs.
Next, we evaluated CLDN11 promoter methylation and
expression in gastric cell lines. Immortalized human normal
gastric epithelial cells (HFE145) and GC cell lines AGS, SIIA,
MKN28, KATOIII, and SNU-1 were studied. All GC cell lines
tested (AGS, SIIA, MKN28, KATOIII, and SNU-1) demonstrat-
ed promoter hypermethylation, whereas no methylation was
observed in immortalized normal HFE145 cells (Figure 2A).
CLDN11 mRNA levels were assessed using qRT-PCR on RNAs
purified from the cell lines, while claudin-11 protein expression
was analyzed by Western blotting. As shown in Figure 2B, all 5
cancer lines exhibited no detectable expression of CLDN11 mRNA
or protein, while HFE145 cells manifested high CLDN11
expression levels. This finding establishes that CLDN11 is
coordinately hypermethylated and downregulated in GC cell lines
relative to normal gastric epithelial cells (NGECs).
To further validate silencing of CLDN11 expression by
hypermethylation, we treated the GC cell line AGS with the
demethylating agent, 5-aza-2-deoxycytidine (5-aza-dC, 1 mM), for
varying time intervals. Total RNAs extracted before vs. after
treatment were subjected to qRT-PCR for CLDN11. As can be
seen in Figure 3, at each time point, CLDN11 mRNA became re-
expressed upon treatment with 5-aza-dC, confirming that CLDN11
is silenced by promoter hypermethylation in AGS GC cells.
Members of the claudin protein family have been implicated in
the regulation of cell adhesion, invasion and migration of cancer
cells [25–27]. Therefore, we next investigated whether CLDN11
influences cell motility or invasiveness. HFE145 cells, which
express abundant CLDN11, were chosen to study effects of
CLDN11 knockdown on the invasive and migratory properties of
gastric epithelial cells. Transient siRNA transfections were carried
out using CLDN11-specific siRNA duplexes. Transfection with
CLDN11-specific siRNA duplexes efficiently repressed claudin-11
protein levels by.90%, whereas expression remained unchanged
in mock- or control siRNA-treated cells (Figure 4A). Cell motility
and invasion assays were conducted on siRNA-transfected cells
using a modified Boyden-chamber assay system [25]. Interestingly,
as shown in Figures 4B and 4C, inhibition of CLDN11
expression in HFE145 cells significantly increased the migratory
and invasive potentials of these cells, respectively.
The current study thus confirms the hypothesis that CLDN11,a
tight junction protein, is silenced in GC via promoter hyper-
methylation, and these data support the involvement of CLDN11
in the control of GC cell invasion and migration.
Promoter hypermethylation is known to be associated with
transcriptional silencing of certain genes. DNA methylation can
interfere with binding of transcription factors whose binding sites
contain CpG dinucleotides. Using the TFSEARCH software
program, we scanned the CLDN11 sequence found to be
hypermethylated in gastric cancer tissues and cell lines, i.e., the
qMSP amplicon (-104 to +4 bases relative to the transcriptional
start site for CLDN11). This scan identified putative binding sites
for Sp1 and GATA-1 and GATA-2. Previous studies have shown
that hypermethylation of promoter DNA contributes to silencing
of CLDN3 and CLDN4 in ovarian cell lines, in part via methylation-
induced disruption of binding of Sp1 to its cognate binding site
(22, 23). In addition, members of the GATA family have been
shown to be positive regulators of CLDN11 transcription [28].
Further studies are now warranted to evaluate whether hyper-
methylation of these sites interferes with the binding of
transcription factors, and how such disruption may influence
CLDN11 gene transcription.
Tumor cells typically exhibit structural and functional deficien-
cies in their TJs [17]. These deficiencies are associated with a loss
of polarity and differentiation. Another important link between
TJs and cancer is a loss of TJ integrity, with consequent leakage or
transport of pro-tumorigenic substances (such as growth factors or
nutrients) into developing tumor cell primordia, promoting tumor
growth [29]. In addition, the loss of polarity, differentiation, and
adhesive properties associated with impaired TJ function in cancer
may be critical in acquiring a metastatic phenotype [30]. Studies
have suggested that anomalies in TJ-associated proteins may
represent epithelial-mesenchymal transition (EMT), thereby
changing the invasiveness and motility of cancer cells.
Modulations in expression of TJ-associated proteins, particularly
claudin proteins, have been shown in a number of cancers. Recent
studies by us and others have shown alterations in claudin protein
regulation in various epithelial cancers [18]. Members of the
claudin gene family are expressed in a highly tissue-specific, as well
as a very developmental stage-specific, manner. In addition,
depending on cancer type, the expression of claudin proteins can
be either upregulated or downregulated in cancer cells. For
example, several claudin proteins are upregulated in colon,
Figure 3. CLDN11 mRNA re-expression in AGS GC cells after 5-
aza-29-deoxycytidine (5-aza-dC) treatment. AGS is a GC cell line
manifesting hypermethylation of the CLDN11 promoter in conjunction
with absent CLDN11 mRNA expression. These cells were treated with 5-
aza-dC, a global demethylating agent. Total RNA from AGS cells before
and after 5-aza-dC treatment were subjected to quantitative real-time
RT-PCR analysis for CLDN11 mRNA expression. The Y-axis represents the
average fold change in expression levels of CLDN11 mRNA after 5-aza-
dC treatment at various time points, when compared with the
untreated cells. AGS cells, when treated with 5-aza-dC, exhibited a
time-dependent increase in CLDN11 mRNA expression up to 72 hrs of
treatment. This restoration of CLDN11 expression after 5-aza-dC
treatment supports our hypothesis that claudin-11 is silenced by
promoter hypermethylation in GC cells.
doi:10.1371/journal.pone.0008002.g003
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downregulated in breast cancer and head and neck cancers [16,18]
Studies have previously reported changes in expression profiles
of members of the claudin family to be associated with GC. Serial
analysis of gene expression (SAGE) identified the CLDN18 gene as
downregulatedin GCs possessingan intestinal phenotype [31]. The
CLDN23 gene is also downregulated in intestinal-type GCs [32].
Conversely, Cunningham et al. reported CLDN4 expression to be
increased in intestinal metaplasia and gastric epithelial dysplasia,
identifying this gene as a marker of GC precursor lesions [33]. In
the current study, we found CLDN11 expression to be downreg-
ulated or silenced in GC via hypermethylation of its promoter
region. Moreover, we found that unlike CLDN18 and CLDN23,
CLDN11 expression was downregulated in GC patient specimens as
well as in cell lines, irrespective of diffuse vs. intestinal subtype.
Claudin-11, also known as oligodendrocyte-specific protein, was
first identified to be specifically expressed in the tight junction
strands of oligodendrocytes in brain and in Sertoli cells of rats and
mice [34,35]. Loss of claudin-11 expression, leading to disruption
of the TJ barrier, is associated with neurological and reproductive
deficits [36]. A recent study reported overexpression and
mislocalization of CLDN11 from the blood–testis barrier in Sertoli
cells to be associated with testicular intraepithelial neoplasia in
men [37]. Data in the current study establishes that CLDN11 is
expressed in normal gastric tissues and immortalized NGECs.
However, its complete functions in normal stomach as well as in
gastric carcinogenesis remain unclear.
In an attempt to explore the possible involvement of CLDN11 in
GC, we studied phenotypic changes associated with silencing of
CLDN11 expression in CLDN11-expressing gastric epithelial cells
Figure 4. Small interfering RNA knockdown experiments. HFE145 cell line, which is claudin-11 positive was selected to study the role of
claudin-11 knockdown on migration and invasion properties of gastric cells. Cells were transfected with CLDN11 specific siRNA oligos. Mock
transfections and nonspecific siRNA duplexes were used as the negative controls. A) Western blot analysis of siRNA mediated claudin-11 knock-down
in HFE145 cells. HFE145 cells were transfected with CLDN11- specific and non-specific control siRNA duplexes, as described in Materials and Methods.
After 48 to 72 hours, total cell lysates were prepared and analyzed for claudin-11 expression. Transfection of claudin-specific siRNA oligos resulted
in.90% reduction in expression of the protein, whereas the levels of claudin protein in the control cells were not significantly altered. B) Boyden
chamber cell invasion assay. The invasiveness of the siRNA-transfected cells were determined using matrigel coated invasion chamber, using a
modified Boyden chamber assay. Experiments were repeated at least three times, with triplicates in each experiment. The data represented here is
the average fold change in invasion of the siRNA-transfected cells when compared with the mock transfections. As is demonstrated in this figure,
siRNA knockdown of claudin-11 leads to an increase in cell invasion of HFE145 cells. C) Two-chamber cell migration assay. The effects of claudin-11
knockdown on migration of the HFE145 cells were compared by measuring the number of cells migrating through the uncoated filters (instead of
matrigel-coated filters). The bars in this figure represent mean fold change in migration of siRNA-transfected cells compared with the mock-
transfected control cells. As can be seen in this figure, a reduction in claudin-11 protein levels is associated with increased motility of the cells.
doi:10.1371/journal.pone.0008002.g004
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CLDN11 resulted in increased cell motility and invasion.
Previous studies have reported cancer-specific phenotypic
changes to be associated with modulations in claudin expression
in various cancer types. Overexpression of claudin-3 and claudin-4
proteins in ovarian cancer cell lines results in increased invasion by
these cells [25]. In colon cancer, increased expression of claudin-1
has been reported, and changes in claudin-1 expression exert
significant effects on the growth of xenografted tumors and
metastases in athymic nude mice [27]. On the other hand,
claudin-7 downregulation in breast cancer has been associated
with increased cellular discohesion and the ability of breast cancer
cells to disseminate [19]. In addition, experiments in pancreatic
cell lines showed that expression of claudin-4 leads to reduced
invasiveness, tumorigenicity, and metastatic potential of these cells
[38]. The reasons for these discrepancies in effect are presently
unclear, but may be related to tissue-specific differences in claudin
function or even to variations in response of different cell lines.
Clearly, members of the claudin family are known to be expressed
in a tissue-specific manner and may exercise divergent effects.
Although in recent years it has become clear that TJs and TJ-
associated proteins have extensive and diverse functional and
physiological activities in normal and cancerous conditions,
molecular mechanisms underlying these activities remain unclear.
TJs are sophisticated intercellular apparatuses capable of recruit-
ing signaling proteins, thereby regulating various cellular processes
including cell growth, differentiation, and tumorigenesis [39], [40].
Claudin proteins directly associate with discrete signal transduc-
tion pathways by interacting with signaling molecules, such as
atypical protein kinase C and Rho proteins, as well as with other
PDZ domain-containing proteins. In ovarian cancer, claudins
modify tumor invasion by regulating MMP activity [25].
In summary, data from the current study identify CLDN11 as a
target of epigenetic modification, as well as a promising biomarker
for gastric cancer early detection, diagnosis, and therapy. These
findings also suggest involvement of CLDN11 downregulation
in carcinogenesis via promotion of cell invasion and motility.
The mechanisms for this phenomenon are subject to further
investigation.
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